AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT01393639

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

A Phase 2 study testing PF-04171327 and prednisone in people with Rheumatoid Arthritis, run by Pfizer at 93 sites in 18 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
PF-04171327 and prednisone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
323 participants
Where
93 sitesin 18 countries
Study dates
27 Sep 2011to 9 Jun 2014
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection.

Who cannot join

  • Subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications;
  • subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.

Trial locations and contacts

93 sites in 18 countries.

93 sites in 18 countries

Russia18 sites
  • Territorial Clinical Hospital

    Barnaul, 656024

  • GBUZ of Kemerovo region Regional clinical hospital for was veterans

    Kemerovo, 650000

  • Kemerovo Regional Clinical Hospital

    Kemerovo, 650066

  • FSBI Scientific - Research Institute of Rheumatology RAMS n.a. V.A. Nasonova.

    Moscow, 115522

  • LLC Consultative and Diagnostic Rheumatological Center Healthy Joints

    Novosibirsk, 630091

  • GBOU VPO "Orenburg State Medical Academy of Ministry of Healthcare of Russian Federation"

    Orenburg, Russian Federation, 460000

  • Republican Hospital V.A.Baranov

    Petrozavodsk, 185019

  • Ryazan Regional Clinical Cardiological Dispensary

    Ryazan, 390026

  • Clinical Rheumatological Hospital #25

    Saint Petersburg, 190068

  • Clinical Hospital #122 L.G. Sokolov

    Saint Petersburg, 194291

  • MUZ City Clinical Hospital #12

    Saratov, 410039

  • Smolensk Regional Clinical Hospital

    Smolensk, 214018

  • Tomsk Regional Clinical Hospital

    Tomsk, 634063

  • Vladimir Regional Clinical Hospital

    Vladimir, 600023

  • Clinical Hospital of Emergency Care N.V. Soloviev

    Yaroslavl, 150003

  • Yaroslavl Regional Clinical Hospital

    Yaroslavl, 150062

  • Sverdlovsk Regional Clinical Hospital # 1

    Yekaterinburg, 620102

  • Municilap Institution Central Clinical Hospital 6

    Yekaterinburg, 620149

Other trials in Russia

United States14 sites
  • Arthritis and Osteoporosis Medical Associates, PLLC

    Brooklyn, New York, 11201

  • Low Country Rheumatology, PA

    Charleston, South Carolina, 29406

  • Tricounty Radiology

    Charleston, South Carolina, 29406

  • Cincinnati Rheumatic Disease Study Group, Inc.

    Cincinnati, Ohio, 45219

  • Allergy, Asthma, Arthritis, and Lung Center

    Daytona Beach, Florida, 32114

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • Accurate Clinical Research, Inc.

    Houston, Texas, 77034

  • Javed Rheumatology Associates, Inc.

    Newark, Delaware, 19713

  • Millennium Research

    Ormond Beach, Florida, 32174

  • C. Michael Neuwelt, MD, Inc.

    San Leandro, California, 94578

  • Arthritis Northwest, PLLC

    Spokane, Washington, 99204

  • Catalina Pointe Clinical Research, Inc.

    Tucson, Arizona, 85704

  • Alastair C. Kennedy, MD

    Vero Beach, Florida, 32960

  • The Center for Arthritis and Rheumatism

    Vero Beach, Florida, 32960

Other trials in United States

Ukraine9 sites
  • Municipal Medical Institution "City Clinical Hospital #3"

    Chernivtsi, 58022

  • Municipal Medicoprophylactic Institution "Donetsk City Clinical Hospital #5".

    Donetsk, 83001

  • National Scientific Centre "Institute of Cardiology n.a. M.D. Strazheska of NAMS of Ukraine".

    Kiev, 03680

  • Komunalnyi zaklad Kyivskoi oblasnoi rady "Kyivska oblasna klinichna likarnia"

    Kyiv, 04107

  • Komunalnyi zaklad Lvivskoi oblasnoi rady "Lvivskyi oblasnyi klinichnyi diahnostychnyi tsentr"

    Lviv, 79010

  • Komunalna ustanova "Odeska oblasna klinichna likarnia"

    Odesa, 65025

  • Municipal Establishment "City Clinical Hospital #9 n.a. O.I. Minakov", Department of Rheumatology

    Odesa, 65026

  • Vinnytsya regional clinical hospital named after M.I. Pyrogova; Department of rheumatology

    Vinnytsia, 21018

  • Municipal Institution:"Zaporizhzhya Regional Clinical Hospital",Rheumatology Dep.

    Zaporizhzhya, 69600

Other trials in Ukraine

Hungary6 sites
  • Dr. Rethy Pal Korhaz es Rendelointezet, II. Reumatologia Szakrendeles

    Békéscsaba, 5600

  • Budai Irgalmasrendi Korhaz, Reumatologia I.

    Budapest, 1027

  • Revita Reumatologiai Rendelo

    Budapest, 1027

  • Qualiclinic Kft.

    Budapest, 1036

  • Fejer Megyei Szent Gyorgy Korhaz Reumatologia

    Székesfehérvár, 8000

  • MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles

    Szolnok, 5000

Other trials in Hungary

Slovakia5 sites
  • AAGS, s.r.o. , nestatne zdravotnicke zariadenie

    Dunajská Streda, 92901

  • Nestatna reumatologicka ambulancia

    Považská Bystrica, 017 01

  • Reumatologicka ambulancia, REUMEX, s.r.o.

    Rimavská Sobota, 979 01

  • Reumaglobal s.r.o.

    Trnava, 917 01

  • Nestatna reumatologicka ambulancia

    Žilina, 010 01

Other trials in Slovakia

South Korea5 sites
  • Daegu Catholic University Medical Center, Department of Rheumatology

    Daegu, 705-718

  • Inha University Hospital, Medicine/Rheumatology

    Incheon, 400-711

  • KyungHee University Hospital

    Seoul, Korea, 130-872

  • Seoul National University Hospital, Rheumatology, Internal Medicine

    Seoul, 110-744

  • Konkuk University Medical Center, Department of Rheumatology

    Seoul, 143-729

Other trials in South Korea

Bulgaria4 sites
  • Revmatologichen kabinet, DKTs Sv. Pantaleimon OOD

    Pleven, 5800

  • Revmatologichno Otdelenie, MBAL - Plovdiv

    Plovdiv, 4000

  • MBAL "Sveti Ivan Rilski" Sofia; Klinika po Revmatologia

    Sofia, 1612

  • MBAL Sveti Ivan Rilski Sofia; Klinika po Revmatologia

    Sofia, 1612

Other trials in Bulgaria

Colombia4 sites
  • Centro Integral de Reumatologia e Inmunologia CIREI

    Bogota, Cundinamarca, 110221

  • Preventive Care SAS

    Chía, Cundinamarca, 250001

  • Hospital Pablo Tobon Uribe

    Medellín, Antioquia

  • Reumalab S.A.S

    Medellín, Antioquia

Other trials in Colombia

Czechia4 sites
  • Revmatologie Bruntal, S.R.O.

    Bruntál, 79201

  • Revmatologicka ambulance

    Ostrava - Poruba, 70800

  • Revmatologicka ambulance

    Prague, 140 00

  • Thomayerova nemocnice

    Prague, 140 59

Other trials in Czechia

Romania4 sites
  • Spitalul Clinic "Sfanta Maria", Clinica de Medicina Interna si Reumatologie

    Bucharest, 800578

  • Spitalul Clinic Judetean de Urgenta "Sfantul Apostol Andrei"

    Galati, 800578

  • Spitalul Clinic de Recuperare

    Iași, 700656

  • Spitalul Clinic Judetean de Urgenta Targu Mures, Reumatologic

    Tg Mures, 540136

Other trials in Romania

Germany3 sites
  • Charite Universitaetsmedizin Berlin, Klinik fuer Rheumatologie

    Berlin, 10117

  • Klinische Forschung Berlin-Buch GmbH

    Berlin, 13125

  • CIRI GmbH

    Frankfurt am Main, 60528

Other trials in Germany

India3 sites
  • Shirdi Sai Hospital

    Bangalore, Karnataka, 560 054

  • Dapartment of Rheumatology

    Lucknow, Uttar Pradesh, 226 018

  • Krishna Institute of Medical Sciences Ltd

    Secunderabad, Andhra Pradesh, 500 003

Other trials in India

Mexico3 sites
  • Centro de Estudios de Investigacion Basica y Clinica SC.

    Guadalajara, Jalisco, 44690

  • Unidad de Investigacion Biomedica del CEM

    Mérida, Yucatán, 97000

  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.

    San Luis Potosí City, 78200

Other trials in Mexico

Poland3 sites
  • Centrum Kliniczno-Badawcze J. Brzezicki, B. Górniakiewicz-Brzezicka Lekarze Spółka Partnerska

    Elblag, 82-300

  • Nzoz "Lecznica Mak-Med S.C."

    Nadarzyn, 05-830

  • Wojewodzki Zespol Reumatologiczny im. dr J. Titz-Kosko

    Sopot, 81-759

Other trials in Poland

Malaysia2 sites
  • Hospital Raja Permaisuri Bainun

    Ipoh, Perak, 30990

  • Sunway Medical Centre

    Petaling Jaya, Selangor, 46150

Other trials in Malaysia

Serbia2 sites
  • Institute of Rheumatology

    Belgrade, 11000

  • Institute for treatment and rehabilitation Niska Banja

    Niška Banja, 18205

Other trials in Serbia

South Africa2 sites
  • Panorama Medical Centre

    Panorama, Cape Town, 7500

  • Emmed Research

    Pretoria, Gauteng, 0084

Other trials in South Africa

Spain2 sites
  • Complejo Hospitalario Universitario A Coruña. Hospital Materno Infantil Teresa Herrera

    A Coruña, 15006

  • Hospital SANITAS CIMA.

    Barcelona, 08034

Other trials in Spain

About this study

Official title: A PHASE 2, RANDOMIZED, DOUBLE BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF 04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMATOID ARTHRITIS OVER AN 8 WEEK PERIOD FOLLOWED BY A 4 WEEK PERIOD OF TAPERING OF STUDY DRUG.

The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.

Being tested
PF-04171327, prednisone, placebo
Keywords
treatment of rheumatoid arthritis, treatment of RA, patients on methotrexate for rheumatoid arthritis, prednisone for rheumatoid arthritis
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PF-04171327Drug

    1 mg tablet once daily (QD) for 8 weeks

  • PF-04171327Drug

    5 mg tablet once daily (QD) for 8 weeks

  • PF-04171327Drug

    10 mg tablet once daily (QD) for 8 weeks

  • PF-04171327Drug

    15 mg tablet once daily (QD) for 8 weeks

  • prednisoneDrug

    5 mg capsule once daily for 8 weeks

  • prednisoneOther

    10 mg capsule once daily for 8 weeks

  • placeboOther

    placebo (tablet or capsule) once daily (QD) for 8 weeks

Study groups in NCT01393639
Study groupRoleWhat they receive
PF-04171327 1 mg QDExperimentalNot described
Receives: Drug: PF-04171327
PF-04171327 5 mg QDExperimentalNot described
Receives: Drug: PF-04171327
PF-04171327 10 mg QDExperimentalNot described
Receives: Drug: PF-04171327
PF-04171327 15 mg QDExperimentalNot described
Receives: Drug: PF-04171327
prednisone 5 mg QDActive comparatorNot described
Receives: Drug: prednisone
prednisone 10 mg QDActive comparatorNot described
Receives: Other: prednisone
placeboPlacebo comparatorNot described
Receives: Other: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8

    ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).

    Measured: Week 8

  2. Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)

    Change from baseline in P1NP at week 8 is presented in this outcome measure.

    Measured: Week 8

  3. Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)

    Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.

    Measured: Week 8

Secondary outcomes (25)
  1. Percentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)

    ACR20 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Measured: Weeks 2, 4, and 12 (taper period)

  2. Percentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)

    ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Measured: Weeks 2, 4, 6, 8, and 12 (taper period)

  3. Percentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)

    ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Measured: Weeks 2, 4, 6, 8, and 12 (taper period)

  4. Change From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Measured: Weeks 2, 4, 6, and 8

  5. Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Measured: Week 12

  6. Change From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Measured: Weeks 2, 4, 6, and 8

  7. Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Measured: Week 12

  8. Change From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)

    The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.

    Measured: Weeks 2, 4, 6, and 8

  9. Change From Baseline of CRP at Week 12 (Descriptive Statistics)

    The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit.

    Measured: Week 12

  10. Change From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Weeks 2, 4, 6, and 8

  11. Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Week 12

  12. Change From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Weeks 2, 4, 6, and 8

  13. Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)

    The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Week 12

  14. Change From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.

    Measured: Weeks 2, 4, 6, and 8

  15. Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)

    Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.

    Measured: Week 12

  16. Change From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Weeks 2, 4, 6, and 8

  17. Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)

    Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Week 12

  18. Change From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.

    Measured: Weeks 2, 4, 6, and 8

  19. Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)

    DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.

    Measured: Week 12

  20. Change From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.

    Measured: Weeks 2, 4, 6, and 8

  21. Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)

    DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.

    Measured: Week 12

  22. Change From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Measured: Weeks 4 and 8

  23. Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Measured: Week 12

  24. Change From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Measured: Weeks 4 and 8

  25. Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Measured: Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2011 (estimated)
  2. Study start27 Sep 2011
  3. Primary completion3 Jun 2014
  4. Study completion9 Jun 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
323 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01393639
Sponsor's protocol ID
A9391010
Other IDs
2010-023782-22
Status last verified
Aug 2024
First submitted
13 Jun 2011
Last updated
4 Sep 2024
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.

    PubMed 31168411

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing PF-04171327 and prednisone in people with Rheumatoid Arthritis, run by Pfizer at 93 sites in 18 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 93 sites in Russia, United States, Ukraine, Hungary, Slovakia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 Sep 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 (time frame: Week 8). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01393639, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in